1 / 28

Medical Nutrition Therapy in Cardiovascular Disease

Chapter 35. Medical Nutrition Therapy in Cardiovascular Disease. Coronary Heart Disease (CHD) or Coronary Artery Disease (CAD) . Disease involving the network of blood vessels surrounding and serving the heart Manifested in clinical end points of myocardial infarction (MI) and sudden death.

kaden-craft
Télécharger la présentation

Medical Nutrition Therapy in Cardiovascular Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 35 Medical Nutrition Therapy in Cardiovascular Disease

  2. Coronary Heart Disease (CHD) or Coronary Artery Disease (CAD) • Disease involving the network of blood vessels surrounding and serving the heart • Manifested in clinical end points of myocardial infarction (MI) and sudden death

  3. Cardiovascular Disease (CVD) • CVD has been the leading cause of death in the United States for every year since 1900, except 1908. • CVD kills almost as many people yearly as the next seven causes of death combined.

  4. Prevalence and Incidence • The United States ranks 14th and 16th, among industrialized nations for the prevalence of CVD in women and men, respectively. • More than 61 million Americans have at least one form of CVD (i.e., hypertension, CHD, stroke, rheumatic heart disease, or congestive heart failure). • The incidence of CHD is high; an American experiences a coronary event almost every 29 seconds.

  5. Natural Progression of Atherosclerosis (From Harkreader H. Fundamentals. Philadelphia: W.B. Saunders, 2000)

  6. Plaque That Has Been Surgically Removed from Coronary Artery Courtesy Ronald D. Gregory and John Riley, MD.

  7. Prevention • Blood lipids and lipoproteins • Total cholesterol • Total triglycerides • Lipoproteins and metabolism —Chylomicrons, VLDL, IDL, LDL, HDL

  8. Functions of the Plasma Lipoproteins • Chylomicron—Transport of dietary triglyceride • VLDL—Transport of endogenous triglyceride • IDL—LDL precursor • LDL—Major cholesterol transport lipoprotein • HDL—Reverse cholesterol transport

  9. Lipoprotein Assessment • Includes measurement of total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride level after fasting

  10. Cardiovascular Risk Factors • Category I—cigarette smoking, LDL cholesterol, high-fat diet, hypertension • Category II—diabetes mellitus, physical inactivity, HDL cholesterol, TG, obesity • Category III—psychosocial factors, lipoprotein a, homocysteine • Category IV—age, male gender, low socioeconomic status, family history

  11. Quantity of Soluble Fiber Needed Daily to Produce Lipid-Lowering Effect • Pectin: 6 to 40 g • Gums: 8 to 36 g • Dried beans or legumes: 100 to 150 g • Dry oat bran: 25 to 100 g • Oatmeal: 57 to 140 g • Psyllium: 10 to 30 g

  12. Genetic Hyperlipidemias • Familial hypercholesterolemia • Familial combined hyperlipidemia • Familial dyslipidemia • Familial dysbetalipoproteinemia

  13. Saturated fat Polyunsaturated fat Monounsaturated fat Total fat Carbohydrate Fiber Protein Cholesterol Total calories (energy) Nutrient Composition of the Therapeutic Lifestyle Change Diet

  14. Category I Risk Factors for Coronary Heart Disease • Cigarette smoking • Elevated LDL and total cholesterol • Hypertension • Left ventricular hypertrophy (LVH) • Thrombogenic factors

  15. Category II Risk Factors for Coronary Heart Disease • Diabetes mellitus types 1 and 2 • Physical inactivity • Low HDL cholesterol • Obesity • Menopausal factors

  16. Major Disease Processes Contributing to Coronary Heart Disease • Atherosclerosis—chronic (long-term development) • Thrombosis—acute (late and brief event)

  17. Pathophysiologic Steps in Development of Coronary Heart Disease/Myocardial Infarction Phase 1 Fatty streaks (atherogenesis) Phase 2 Atheroma (or plaque) formation Phase 3 Complicated lesions with rupture (nonocclusive thrombosis) Phase 4 Complicated lesions with rupture and occlusive thrombosis Phase 5 Fibrosis (occlusive) lesions

  18. Hyperlipidemias • Elevated blood triglycerides and/or cholesterol • Lipoproteins found in blood • Chylomicrons = postprandial dietary fat • Very-low-density lipoproteins (VLDL) = lipid being transported from liver to peripheral tissue • Low-density lipoproteins (LDL) = transport of cholesterol • High-density lipoproteins (HDL) = reverse transport of cholesterol, tissues to liver • Type of hyperlipidemia depends upon portion of particles present

  19. LDL and HDL CholesterolLaboratory Values Predict Risk of CHD • LDL-C >130 mg/dl • HDL-C <35 mg/dl • Total cholesterol (TC) >200 mg/dl • Total triglycerides (TG) >150 mg/dl • Formula: LDL-C = TC – HDL-C–(TG/5)

  20. HDL Cholesterol Levels Predict Risk of Coronary Heart Disease • Increased by: Exercise Weight loss Moderation of alcohol • Decreased by: Obesity No exercise Cigarettes Androgenic steroids B blockers High TGs Genetic factors

  21. LDL Cholesterol Levels Predict Risk of Coronary Heart Disease • Increased by • Fat in diet • Obesity • Diabetes • Hypothyroidism • Decreased by • Estrogen

  22. Primary Prevention with Lipoprotein Analysis (From National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). National Institutes of Health, NIH Publication No. 93-3095. Bethesda, MD: National Heart, Lung, and Blood Institute, 1993.)

  23. Primary Prevention in Adults without Evidence of CHD: Initial Classification Based on Total Cholesterol and HDL Cholesterol (From National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). National Institutes of Health, NIH Publication No. 93-3095. Bethesda, MD: National Heart, Lung, and Blood Institute, 1993.) HDL = high-density lipoprotein.

  24. Diet Therapy for High Blood Cholesterol (Data from National Cholesterol Education Program [NCEP]. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel II]. NIH Publication N. 93-3095. Bethesda, MD; National Institutes of Health. National Heart, Lung, and Blood Institute, 1993.) * Calories from alcohol not included.

  25. General Goals for Treatment of Hyperlipidemias • Achieve IBW. • Decrease simple sugars and alcohol. • Decrease total fat, especially cholesterol and SFA. • Increase complex carbohydrate and fiber.

  26. Lipid-Lowering DrugsAdded if Diets Are Not Successful • After a 6-month trial on each diet, drugs are added to the treatment. • Types: • Nicotinic acid and lovastatin • Gemfibrozil, probucol, clofibrate—for high TGs • Cholestyramine and colestipol (bile acid sequestrants)—to lower high cholesterol; may increase TGs

  27. Myocardial Infarction (MI)Coronary Infarction, Coronary Thrombosis, or Heart Attack • Some part of coronary circulation blocked • Ischemia leads to muscle destruction • Diagnosis: ECG; blood levels of enzymes such as LDH and CPK

  28. Myocardial Infarction—MI Postinfarction nutrition 1. 1st 24 hrs: no caffeine, liquid diet (nausea and choking are common) 2. Small frequent meals; soft or liquid diet 3. Na+ restriction if BP and fluid status indicate 4. Consistent diet information 5. Drugs that cause nausea—digitalis, morphine

More Related